<![CDATA[Disease Biology, Aromatase Inhibitor-Driven Resistance, and ESR1 Emergence]]>

ConferenceCDK4/6 inhibitorAromatase inhibitorNeutral

AI Analysis

Summary

Faculty discussion on disease biology and treatment mechanisms in hormone receptor-positive, HER2-negative metastatic breast cancer, focusing on CDK4/6 inhibitors combined with aromatase inhibitors and resistance development.

Importance:2/10

Sentiment:

0.00

breast cancerhormone receptor-positiveHER2-negativemetastaticCDK4/6 inhibitoraromatase inhibitordisease biologydrug resistance

Related Companies

$INTI

Read the original article

Published by Cancer Network on July 31, 2026 6:00 PM

Read Original